New & Noteworthy

September-October 2014

Line Immunoassay Technology for Lyme Testing

Gold Standard Diagnostics

Gold Standard Diagnostics (GSD), announces new Line Immunoassay technology for Lyme confirmation testing, giving clinical laboratories an FDA-cleared option for serological confirmation testing for Lyme disease according to the CDC-recommended two-step process. Both the IgG and IgM line blots are substantially equivalent to traditional Western Blot technology, but offer advancements in usability and objectivity through use of Line Immunoassay technology. GSD's LIA test strips offer improved sensitivity and specificity, consistent results, large lot sizes, easier handling, and automation options. Clear bands for each antigen, a serum control band, and a cutoff control band make it easy to interpret each sample result, and strips can be scanned and interpreted by GSD software. The 10 IgG antigens match CDC requirements for testing for general infection as well as determination of the stage of infection. All three IgM proteins are included for early and disseminated Lyme disease diagnosis. Strips are affixed in a booklet and the unique numbering system makes working with GSD's Lyme line blots simple regardless of testing volume.

Request More Information

Current Issue